Deals in Depth: November 2009
In an alliance worth $849 million in pre-commercialization money, BMS added another rheumatoid arthritis therapeutic to its pipeline, Alder's Phase IIa ALD518. The top two pharma M&As were in the specialty pharmaceutical space--Biovitrum/Swedish Orphan and Enzon/Sigma-Tau. Meanwhile, Stryker got into the medical device reprocessing market via its acquisition of Ascent. And pharma and device financing were both down from the previous month (although October did boast several big outlier deals).
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.